Seshadri Neervannan Ph.D.
Net Worth
Last updated:
What is Seshadri Neervannan Ph.D. net worth?
The estimated net worth of Dr. Seshadri Neervannan Ph.D. is at least $3,939,206 as of 23 Mar 2023. He owns shares worth $2,937,175 as insider, has earned $28,691 from insider trading and has received compensation worth at least $973,340 in Tarsus Pharmaceuticals, Inc..
What is the salary of Seshadri Neervannan Ph.D.?
Dr. Seshadri Neervannan Ph.D. salary is $486,670 per year as Chief Operating Officer in Tarsus Pharmaceuticals, Inc..
How old is Seshadri Neervannan Ph.D.?
Dr. Seshadri Neervannan Ph.D. is 57 years old, born in 1968.
What stocks does Seshadri Neervannan Ph.D. currently own?
As insider, Dr. Seshadri Neervannan Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | Chief Operating Officer | 54,696 | $53.7 | $2,937,175 |
What does Tarsus Pharmaceuticals, Inc. do?
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Seshadri Neervannan Ph.D. insider trading
Tarsus Pharmaceuticals, Inc.
Dr. Seshadri Neervannan Ph.D. has made 6 insider trades in 2023, according to the Form 4 filled with the SEC. Most recently he sold 390 units of TARS stock worth $4,739 on 23 Mar 2023.
The largest trade he's ever made was exercising 5,097 units of TARS stock on 15 Mar 2023. As of 23 Mar 2023 he still owns at least 54,696 units of TARS stock.
Tarsus Pharmaceuticals key executives
Tarsus Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Seshadri Neervannan Ph.D. (57) Chief Operating Officer
- Mr. Leonard M. Greenstein (49) Chief Financial Officer